Peptide Pipeline
Clinical trial · ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) Compared With Semaglutide in Participants With Type 2 Diabetes

NCT03954834

Trial identity

Registry
ClinicalTrials.gov
Registry ID
NCT03954834
Phase
Phase 3
Design
Interventional
Allocation
Randomized
Masking
Open-label
Overall status
Completed
Result status
published

Sponsors & collaborators

Sponsor
Eli Lilly
Collaborators
—

Intervention assets

Tirzepatide

Once-weekly dual GIP and GLP-1 receptor agonist that improves glycemic control and drives weight loss.

Semaglutide

Long-acting GLP-1 receptor agonist with amino-acid substitutions and fatty-acid side chain for albumin binding.

Arms

ArmInterventionEnrollment
Tirzepatide 5 mgtirzepatide 5 mg once weekly470
Tirzepatide 10 mgtirzepatide 10 mg once weekly469
Tirzepatide 15 mgtirzepatide 15 mg once weekly469
Semaglutide 1 mgsemaglutide 1 mg once weekly468

Population & enrollment

Population summary
Adults with type 2 diabetes and inadequate glycemic control on metformin.
Eligibility summary
HbA1c 7.0-10.5%, BMI ≥25 kg/m², on stable metformin dose.
Planned enrollment
1876
Actual enrollment
1876

Endpoints

Primary endpoint

Change in HbA1c from baseline at 40 weeks

Secondary endpoints

Body weight change

Fasting serum glucose

Dates

Start date
May 17, 2019
Primary completion
Feb 10, 2021
Completion date
Apr 29, 2021
Last synced
Aug 15, 2024

Locations

  • United States
  • Multiple countries

Plain-language interpretation

A Study of Tirzepatide (LY3298176) Compared With Semaglutide in Participants With Type 2 Diabetes is a Phase 3 Interventional sponsored by Eli Lilly. It is evaluating Tirzepatide and Semaglutide in Adults with type 2 diabetes and inadequate glycemic control on metformin.. The primary endpoint is Change in HbA1c from baseline at 40 weeks.

Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.

Sources